GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evofem Biosciences Inc (OTCPK:EVFM) » Definitions » Net Change in Cash

Evofem Biosciences (Evofem Biosciences) Net Change in Cash : $-0.85 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Evofem Biosciences Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Evofem Biosciences's Net Change in Cash for the three months ended in Mar. 2024 was $0.11 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.85 Mil.

Evofem Biosciences Net Change in Cash Historical Data

The historical data trend for Evofem Biosciences's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evofem Biosciences Net Change in Cash Chart

Evofem Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.86 55.63 -58.66 -8.81 -4.20

Evofem Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.24 -0.90 -0.23 0.17 0.11

Evofem Biosciences Net Change in Cash Calculation

Evofem Biosciences's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-8.968+-0.004+4.776+0
=-4.20

Evofem Biosciences's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=0.123+-0.014+0+0
=0.11

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evofem Biosciences Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Evofem Biosciences's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Evofem Biosciences (Evofem Biosciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evofem Biosciences Inc (OTCPK:EVFM) » Definitions » Net Change in Cash
Comparable Companies
CNBX KRBP RBSH INFIQ MYMX HGEN RSPI PPCB CALA BLPH OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Website
https://www.evofem.com
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
Executives
Yan Zhang officer: Chief Financial Officer 6166 TIKI CT, SAN DIEGO CA 92130
Kim P. Kamdar director, 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Jenny C. Yip director 12400 HIGH BLUFF DR., STE. 600, SAN DIEGO CA 92130
Atkinson Katherine Cocca officer: Chief Commercial Officer 12400 HIGH BLUFF., STE. 600, SAN DIEGO CA 92130
Saundra L Pelletier director, officer: Chief Executive Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Alexander A Fitzpatrick officer: General Counsel and Secretary 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Justin J. File officer: Chief Financial Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Anthony Stephen O'brien director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Russell Barrans officer: Chief Commercial Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Dale Rarick director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, STE 600, SAN DIEGO CA 92130
William Walmsley Hall director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DIRVE, SUITE 600, SAN DIEGO CA 92130
Invesco Ltd. 10 percent owner 1331 SPRING STREET NW, SUITE 2500, ATLANTA GA 30309
Link Fund Solutions Ltd 10 percent owner 65 GRESHAM STREET, LONDON X0 EC2V 7NQ
Acacia Research Corp 10 percent owner 767 3RD AVENUE, 6TH FLOOR, NEW YORK NY 10017
Kelly Culwell officer: Chief Medical Officer C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130